NeoPharm, Inc. today announced that the first preliminary Phase I human clinical data on the Company’s novel tumor-targeting agent – SS1(dsFv)-PE38 – was unveiled at the 38th American Society of Clinical Oncology (ASCO) Annual Meeting held in Orlando, Fla. from May 18-21, 2002. This early Phase I scientific and pharmacokinetic data on SS1(dsFv)-PE38, currently being
Archive for the 'NeoPharm, Inc.' Category
Last update: April 01, 2019. 03:30:08 pm.